Viking Therapeutics has announced promising results from its Phase 2 clinical trial of VK2735, an oral tablet designed to aid weight loss in patients with obesity. The drug demonstrated significant body weight reductions compared to placebo over 13 weeks, impressing with safety and tolerability.
This dual agonist targeting GLP-1 and GIP receptors offers a novel approach in metabolic therapy, showing no plateau in weight loss progress while maintaining a strong safety profile.
What are the key findings from Viking’s VK2735 trial?
Results from the VENTURE-Oral Dosing trial showed that patients receiving VK2735 had an average weight loss of up to 12.2%, equivalent to 26.6 pounds, after 13 weeks. This contrasts sharply with the 1.3% average loss seen in the placebo group.
Significantly, 97% of patients on VK2735 reached at least 5% weight loss, and 80% achieved a weight loss of 10% or more. These figures highlight VK2735’s potential to deliver meaningful clinical outcomes.
Did you know?
Up to 97% of patients treated with VK2735 achieved at least 5% weight loss, a milestone rarely seen in oral obesity drugs.
How does VK2735 impact obesity treatment prospects?
VK2735’s once-daily oral dosing regimen marks a potential breakthrough, providing an effective alternative to injectable therapies common in obesity management.
The progressive weight loss with no observed plateau through the study period suggests sustained efficacy. If these results hold in later-stage studies, this could change the treatment landscape for millions worldwide struggling with obesity.
ALSO READ | Could Syn57 bacteria point to a future of virus-proof life?
Viking confirms VK2735’s safety in oral dosing trial
Safety data from the 13-week trial confirm that VK2735 is well-tolerated, with nearly all gastrointestinal side effects classified as mild or moderate.
No serious adverse events were reported related to the drug, which supports its use in broader populations and reinforces confidence in its clinical development path.
Significant weight loss demonstrated with VK2735
The noticeable decreases compared to the placebo and starting point strongly show that VK2735 works at all doses above 15 mg.
The findings are a crucial step forward for Viking Therapeutics, highlighting their potential to deliver an accessible oral medication addressing the global obesity epidemic with safety and strong efficacy.
Viking’s upcoming conference call will provide further insights, but the Phase 2 VENTURE-Oral trial already signals a hopeful future for patients and healthcare providers alike.
Comments (0)
Please sign in to leave a comment